EXO+: A new startup born out of IBR will be funded by SF500

Claudia Banchio y Hugo Gramajo

EXO+ is focused on developing pharmacological products for the preventive or regenerative treatment of neurons, and therapies for acute and chronic diseases of the central nervous system.

The SF500 Investment Committee will finance Exo+, a project led by IBR researchers Claudia Banchio and Hugo Gramajo.

The venture is based on the results of scientific and technological studies carried out by the group led by Dr. Banchio at IBR, which demonstrate that certain molecules are capable of inducing the differentiation of neural stem cells into functional neurons.

Congratulations Claudia and Hugo on this achievement!